March 28 (Reuters) - The European Union's drugs
regulator on Friday rejected Eli Lilly's ( LLY ) Alzheimer's
drug Kisunla, saying the risk of serious brain swelling did not
outweigh the treatment's small impact on slowing cognitive
decline.
(Reporting by Mariam Sunny and Padmanabhan Ananthan in
Bengaluru; Editing by Shreya Biswas and Sriraj Kalluvila)